drugset
drugset / Trial / NCT02304484

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

NCT02304484 ↗

Phase 3 Completed 770 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to characterize the safety and tolerability of long-term administration of evolocumab in adults with known coronary artery disease and hypercholesterolemia.

Timeline

Start
2014-11-24
Primary completion
2018-03-09
Completion
2018-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Evolocumab Monoclonal antibody 420 mg Subcutaneous

Indications

hyperlipidemia